Aadi Bioscience Inc has a consensus price target of $33.67 based on the ratings of 5 analysts. The high is $51 issued by Ladenburg Thalmann on September 14, 2021. The low is $5 issued by Piper Sandler on December 15, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on December 15, 2023, November 13, 2023, and August 10, 2023, respectively. With an average price target of $28.67 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 1647.97% upside for Aadi Bioscience Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/14/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns | — | Reiterates | → Neutral | Get Alert |
12/15/2023 | Buy Now | 204.88% | Piper Sandler | Joseph Catanzaro | $30 → $5 | Maintains | Overweight | Get Alert |
12/15/2023 | Buy Now | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
11/13/2023 | Buy Now | 2095.12% | HC Wainwright & Co. | Robert Burns | $45 → $36 | Maintains | Buy | Get Alert |
08/10/2023 | Buy Now | 2643.9% | HC Wainwright & Co. | Robert Burns | → $45 | Reiterates | Buy → Buy | Get Alert |
06/08/2023 | Buy Now | 2643.9% | HC Wainwright & Co. | Robert Burns | → $45 | Reiterates | Buy → Buy | Get Alert |
05/17/2023 | Buy Now | 2643.9% | HC Wainwright & Co. | Robert Burns | → $45 | Reiterates | Buy → Buy | Get Alert |
03/29/2023 | Buy Now | 2643.9% | HC Wainwright & Co. | Robert Burns | $48 → $45 | Maintains | Buy | Get Alert |
04/11/2022 | Buy Now | 2826.83% | HC Wainwright & Co. | Robert Burns | $735 → $720 | Maintains | Buy | Get Alert |
01/11/2022 | Buy Now | 2643.9% | Jefferies | Roger Song | → $675 | Initiates | → Buy | Get Alert |
11/24/2021 | Buy Now | 2887.8% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
10/01/2021 | Buy Now | — | Cowen & Co. | Boris Peaker | — | Initiates | → Outperform | Get Alert |
09/14/2021 | Buy Now | 3009.76% | Ladenburg Thalmann | — | — | Initiates | → Buy | Get Alert |
09/08/2021 | Buy Now | 2643.9% | Piper Sandler | Joseph Catanzaro | — | Initiates | → Overweight | Get Alert |
08/30/2021 | Buy Now | 2765.85% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
The latest price target for Aadi Bioscience (NASDAQ:AADI) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $0.00 expecting AADI to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Aadi Bioscience (NASDAQ:AADI) was provided by HC Wainwright & Co., and Aadi Bioscience reiterated their neutral rating.
There is no last upgrade for Aadi Bioscience
The last downgrade for Aadi Bioscience Inc happened on December 15, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Aadi Bioscience Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aadi Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aadi Bioscience was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
While ratings are subjective and will change, the latest Aadi Bioscience (AADI) rating was a reiterated with a price target of $0.00 to $0.00. The current price Aadi Bioscience (AADI) is trading at is $1.64, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.